Alembic Pharma receives final approval from USFDA for generic Mesalamine extended-release capsules

The approved drug is therapeutically equivalent to Salix Pharmaceuticals Inc's reference listed drug (RLD), Apriso extended-release capsules, 0.375 g, it added. The drug has an estimated market size of USD 133 million for the months ended June 2022, Alembic said citing IQVIA data.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news